Protocol ULYM18086, Phase II study of acalabrutinib and high frequency low dose subcutaneous rituximab in patients with previously untreated CLL/SLL¶
University of Rochester. (2022). Protocol ULYM18086, Phase II study of acalabrutinib and high frequency low dose subcutaneous rituximab in patients with previously untreated CLL/SLL.
Cited by¶
1 citation across 1 artifact.
Each citation links to the sentence it supports in the citing article.
Domain-specific¶
- Binomial Proportion Estimation
- Neither source proves that its real observations truly are independent with one shared \(p\); the binomial law is an explicit working condition in each case.
This sourceOriginal protocol inspected. It states planned endpoints, denominator rules, exact-binomial interval and design assumptions; it is not a results report.
- Neither source proves that its real observations truly are independent with one shared \(p\); the binomial law is an explicit working condition in each case.
Verification¶
Does it exist? Not checked yet. This entry carries no identifier to resolve. It was extracted from the citation as written in the article, normalized, and deduplicated against the rest of the registry.
Does it back the claim? Not recorded. The single citation of this work carries no recorded support check.
Support is checked per citation rather than per work — the same source can be cited soundly in one article and wrongly in another. Per-citation recording began recently, so a citation with no recorded check is a gap in the record rather than evidence it went unchecked.
See how references were verified.
Registry ID ref:78f28885d49e · see in the full table